The meta-analysis results could provide new insight into the biology of TERT promoter mutations and understanding of the clinical significance of these mutation carriers, and offer implications for the design of clinical trials, particularly those of anticancer targeted agents for the TERT promoter in aggressive thyroid cancers. This evidence concerns the gene TERT and thyroid cancer.